FIP-WHO META Istanbul, Turkey September 5, 2009 1
Normita D. Leyesa, RPh, MS
President, Philippine Pharmacists Association
MeTA Council Member
Transparency and PharmaceuticalTransparency and Pharmaceutical
Practice from a MeTA Country:Practice from a MeTA Country:
The MeTA Philippines Country ReportThe MeTA Philippines Country Report
1

FIP-WHO META Istanbul, Turkey September 5, 2009 2
Medicine Transparency AllianceMedicine Transparency Alliance
(MeTA) initiative proposes to(MeTA) initiative proposes to
improve accessimprove access to medicinesto medicines
throughthrough transparencytransparency andand
accountabilityaccountability..

FIP-WHO META Istanbul, Turkey September 5, 2009 33
The Philippines WorkThe Philippines Work
Plan for the Phase IPlan for the Phase I
2009-20102009-2010
Objective:Objective:
Provide adequate information that
would strengthen decision-making and
implementation of processes along the
medicines registration, selection,
procurement, and use.

FIP-WHO META Istanbul, Turkey September 5, 2009 4
Preparation ofPreparation of
the Work Planthe Work Plan
 Identification of priority areas for MeTAIdentification of priority areas for MeTA
intervention by scoping visits, consultations, andintervention by scoping visits, consultations, and
stakeholder mappingstakeholder mapping
 Identification of areas supported by otherIdentification of areas supported by other
international development partners andinternational development partners and
stakeholdersstakeholders
 Line-up of activities and allocated budget wereLine-up of activities and allocated budget were
finally deliberated and approvedfinally deliberated and approved

FIP-WHO META Istanbul, Turkey September 5, 2009 5
Three Key Points ofThree Key Points of
Phase IPhase I
1.1. Country structure and commitmentCountry structure and commitment
2.2. Transparency: disclosure, data collectionTransparency: disclosure, data collection
and analysisand analysis
3.3. Accountability: multi-stakeholderAccountability: multi-stakeholder
approach and good governanceapproach and good governance

FIP-WHO META Istanbul, Turkey September 5, 2009 6
2009-20102009-2010
Strategic Work PlanStrategic Work Plan
 Developing Information on Prices, Availability,Developing Information on Prices, Availability,
Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use
 Generating Information to Improve Quality ofGenerating Information to Improve Quality of
PharmaceuticalsPharmaceuticals
 Setting up Systems for Transparency in MedicinesSetting up Systems for Transparency in Medicines
Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage
 Supporting Transparency Agenda in DecentralizedSupporting Transparency Agenda in Decentralized
SystemsSystems
 Preparation of Budget for the ActivitiesPreparation of Budget for the Activities

FIP-WHO META Istanbul, Turkey September 5, 2009 7
KEY OUTCOMESKEY OUTCOMES

FIP-WHO META Istanbul, Turkey September 5, 2009 8
Key Outcome 1:Key Outcome 1:
Available information onAvailable information on
medicines quality, registration,medicines quality, registration,
access, promotions, and rationalaccess, promotions, and rational
drug usedrug use
 Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing)
 Conduct of Level II and III Survey on medicinesConduct of Level II and III Survey on medicines
(ongoing)(ongoing)
 Assessment of Public SectorAssessment of Public Sector
– Procurement (including PITC) of medicinesProcurement (including PITC) of medicines
– Design ofDesign of ee-procurement system-procurement system
– Assessment of the current systems for financingAssessment of the current systems for financing
medicines for the poor (TOR)medicines for the poor (TOR)
 Survey of quality of medicines using the “FDA in aSurvey of quality of medicines using the “FDA in a
suitcase”suitcase”
 Study on medicines promotion and advertisementStudy on medicines promotion and advertisement
(TOR)(TOR)

FIP-WHO META Istanbul, Turkey September 5, 2009 9
Key Outcome 2:Key Outcome 2:
Setting up of informationSetting up of information
structures and systemsstructures and systems
 Improvement of the medicines registrationImprovement of the medicines registration
 FDA websiteFDA website
 Philippine National Drug Formulary WebsitePhilippine National Drug Formulary Website
 Support to the implementation of the ElectronicSupport to the implementation of the Electronic
Essential Drug Price Monitoring System (E-EDPMS) atEssential Drug Price Monitoring System (E-EDPMS) at
the regional and provincial levelsthe regional and provincial levels
 Development of systems for monitoring andDevelopment of systems for monitoring and
evaluation of ethical practices of industry and theevaluation of ethical practices of industry and the
medical professionmedical profession
 Development and testing of monitoring tools forDevelopment and testing of monitoring tools for
prescription auditsprescription audits

FIP-WHO META Istanbul, Turkey September 5, 2009 10
Key Outcome 3:Key Outcome 3:
Improvement of technicalImprovement of technical
capacity for disclosure, analysis, andcapacity for disclosure, analysis, and
the use of information and evidencethe use of information and evidence
 Pharmaceutical Management and Good GovernancePharmaceutical Management and Good Governance
Course for LGU Health Managers and Local ChiefCourse for LGU Health Managers and Local Chief
ExecutivesExecutives
 National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards
 Strengthening of Drug Therapeutic Committees (DTC) atStrengthening of Drug Therapeutic Committees (DTC) at
Regional and Provincial levelsRegional and Provincial levels
 Technical capacity building for DTCsTechnical capacity building for DTCs
 Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs
 Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book

FIP-WHO META Istanbul, Turkey September 5, 2009 11
Key Outcome 4:Key Outcome 4:
Setting up mechanism forSetting up mechanism for
advocacy and participation inadvocacy and participation in
decision making processesdecision making processes
 MeTA Roundtable discussionsMeTA Roundtable discussions
 PublicationsPublications
– Development of the MeTA WebsiteDevelopment of the MeTA Website
– Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum
– Publication of Baseline AssessmentsPublication of Baseline Assessments
 Annual MeTA ForumAnnual MeTA Forum

FIP-WHO META Istanbul, Turkey September 5, 2009 12
Key Outcome 5:Key Outcome 5:
Sustaining a Multi-stakeholderSustaining a Multi-stakeholder
CollaborationCollaboration
 MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations
 Support to Civil Society OrganizationsSupport to Civil Society Organizations
– Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency

FIP-WHO META Istanbul, Turkey September 5, 2009 13
““The challenges in transparency andThe challenges in transparency and
accountability on medicine registration,accountability on medicine registration,
selection, procurement, and use in theselection, procurement, and use in the
Philippines are enormous.Philippines are enormous.
These can be summed up into two:These can be summed up into two: non-non-
accessibility of dataaccessibility of data to policy, decisionto policy, decision
makers, and consumers and themakers, and consumers and the lack oflack of
tools and structurestools and structures for adequatefor adequate
reporting, disclosure and feedback.”reporting, disclosure and feedback.”

FIP-WHO META Istanbul, Turkey September 5, 2009 14
With the assistance of MeTAWith the assistance of MeTA
International, and the Department ofInternational, and the Department of
International Development (DFID) UK,International Development (DFID) UK,
and the support of the World Healthand the support of the World Health
Organization, we will be able toOrganization, we will be able to
surmount these challenges andsurmount these challenges and
ultimately, improve the healthcareultimately, improve the healthcare
delivery system in the Philippines fordelivery system in the Philippines for
the benefit of the Filipino people.the benefit of the Filipino people.

FIP-WHO META Istanbul, Turkey September 5, 2009 15
Thank You!Thank You!